Repligen Corporation RGEN
Updated: 8 Sep 2026
No signal published yet
We already track Repligen and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Repligen Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Repligen free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 22, 2026, Repligen announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion to expand its cell therapy capabilities. On July 28, 2026, the company reported its second quarter 2026 financial results with revenue reaching $204.1 million, representing 13% organic growth year-over-year. Management also updated its full-year 2026 guidance following continued momentum in order intake.
What Firelda Watch includes for Repligen Corporation
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Repligen Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Repligen free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more